The new technology to generate dendritic cells with natural killer cell activity

2014 Fiscal Year Final Research Report

• Project/Area Number: 24501330
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor immunology
• Research Institution: Shinshu University
• Principal Investigator: SHIMODAIRA Shigetaka 信州大学, 学術研究院医学系(医学部附属病院), 准教授 (80345751)
• Co-Investigator(Renkei-kenkyūsha): NISHIMURA Takashi 北海道大学, 遺伝子病制御研究所, 教授 (30143001)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 樹状細胞 / キラー活性 / がん免疫療法 / インターフェロン / G-CSF

Outline of Final Research Achievements

Dendritic cell (DC)-based immunotherapy has been developed against various types of cancers as an active immunotherapy. Cancer vaccination therapies with autologous monocyte-derived mature DCs are principally attributed to the presence of tumor-associated antigens.
The following issues for clinical use may be raised: 1) Manufacturing of DCs; 2) Peptides that target cancer-associated antigens for any cancer patient; 3) Quality of immunological analyses as proof of concept; and 4) Optimization of DC vaccines as add-ons to chemotherapeutic drugs and/or radiotherapy.
Different from the conventional adherent system for GM-CSF and IL-4, the new technology has been progressed to generate DCs induced by interferon (IFN) with natural killer cell activity (killer-DC). This would contribute to the development of future cancer vaccination technology in Japan.

Free Research Field

がん免疫療法